In a recent interview, JK cosmetics co-founder and chief executive officer Shashi Kishore said that his company was not planning to launch a new line of products anytime soon.

But, he also admitted that he was “troubled” by the fact that there was a huge amount of concern about a possible outbreak in the US.

“There’s a lot of concern that the US government is trying to push these vaccines, vaccines in particular, and the fact is, the US is one of the largest producers of vaccine production in the world,” Kisho told CNBC in an interview on Wednesday.

“And the fact of the matter is, there’s not a lot that they can do about it, because there are enough manufacturing facilities to make these vaccines.”

The fear over the possible outbreak has been growing.

Just last month, the FDA said that there were no new confirmed cases of the coronavirus in the United States since the end of February.

It also confirmed that there have been no confirmed cases in the UK, France or Spain.

In its response to the news, Kishoo said that the company had received many requests from doctors to be able to supply vaccine doses to people with certain conditions, but it was not feasible.

The CEO also claimed that the vaccine has no side effects, despite the FDA ruling.

“It’s very clear that this vaccine is not a vaccine that you should be taking,” he said.

“It is an anti-viral vaccine.

It is not designed to protect you from coronaviruses, but to prevent you from getting them.”

Kishore also acknowledged that it was likely that the coronovirus had reached the UK before it was cleared from the US, which is why the company has said it will be launching a new product line.

“We are trying to take advantage of the fact we can do so,” he added.

“So I can’t go back in the business of making the vaccine in the USA and I can only offer it to those who have an emergency situation.”

Kasho’s comments come as a number of experts are urging the US to take a hard line on the threat of the virus and ramp up production of vaccines.

Earlier this month, a group of leading US pharmaceutical industry experts wrote a letter to President Donald Trump urging him to declare a public health emergency, which would allow the government to take actions such as ordering the suspension of the production of the vaccine and issuing warnings to businesses and consumers.